A phase II study of bevacizumab with nab-paclitaxel in patients with recurrent, platinum-resistant primary epithelial ovarian or primary peritoneal carcinoma

被引：0
|
作者：
Tillmanns, T. D.
Lowe, M. P.
Schwartzberg, L. S.
Walker, M. S.
Stepanski, E. J.
机构：
[1] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA
[2] West Clin, Memphis, TN USA
[3] ACORN Res, Memphis, TN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5009
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer
    Roque, Dana M.
    Siegel, Eric R.
    Buza, Natalia
    Bellone, Stefania
    Silasi, Dan-Arin
    Huang, Gloria S.
    Andikyan, Vaagn
    Clark, Mitchell
    Azodi, Masoud
    Schwartz, Peter E.
    Rao, Gautam G.
    Reader, Jocelyn C.
    Hui, Pei
    Tymon-Rosario, Joan R.
    Harold, Justin
    Mauricio, Dennis
    Zeybek, Burak
    Menderes, Gulden
    Altwerger, Gary
    Ratner, Elena
    Santin, Alessandro D.
    BRITISH JOURNAL OF CANCER, 2022, 126 (12) : 1695 - 1703
  • [42] Camrelizumab plus nab-paclitaxel in platinum-resistant patients with unresectable locally advanced or metastatic urothelial carcinoma: A multicentre, single-arm, phase II study
    Li, H.
    Chen, M.
    Xue, C.
    Li, L.
    Hu, A.
    Yang, W.
    Zheng, Z.
    Ni, M.
    Zhang, L.
    Zeng, Y.
    Peng, J.
    Yao, K.
    Zhou, F.
    Liu, Z.
    An, X.
    Shi, Y.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1335 - S1335
  • [43] A randomised, double-blind, phase II study of two doses of pemetrexed in the treatment of platinum-resistant, epithelial ovarian or primary peritoneal cancer
    Vergote, Ignace
    Calvert, Hilary
    Kania, Marek
    Kaiser, Christopher
    Zimmermann, Annamaria Hayden
    Sehouli, Jalid
    EUROPEAN JOURNAL OF CANCER, 2009, 45 (08) : 1415 - 1423
  • [44] Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant epithelial ovarian and primary peritoneal cancers
    Coleman, RL
    Broaddus, RR
    Bodurka, DC
    Wolf, JK
    Burke, TW
    Kavanagh, JJ
    Levenback, CF
    Gershenson, DM
    GYNECOLOGIC ONCOLOGY, 2006, 101 (01) : 126 - 131
  • [45] Phase II study of CT-2103 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma
    Sabbatini, P
    Aghajanian, C
    Dizon, D
    Anderson, S
    Dupont, J
    Brown, JV
    Peters, WA
    Jacobs, A
    Mehdi, A
    Rivkin, S
    Eisenfeld, AJ
    Spriggs, D
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (22) : 4523 - 4531
  • [46] PEGYLATED LIPOSOMAL DOXORUBICIN FOR PLATINUM-RESISTANT OR REFRACTORY MULLERIAN CARCINOMA (EPITHELIAL OVARIAN CARCINOMA, PRIMARY CARCINOMA OF FALLOPIAN TUBE AND PERITONEAL CARCINOMA)
    Wada, T.
    Fukuda, T.
    Kawanishi, M.
    Imai, K.
    Tasaka, R.
    Yamauchi, M.
    Kasai, M.
    Hashiguchi, Y.
    Ichimura, T.
    Deguchi, M.
    Yasui, T.
    Sumi, T.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2015, 25 (09) : 429 - 429
  • [47] A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study
    Biagi, J. J.
    Oza, A. M.
    ChalChal, H. I.
    Grimshaw, R.
    Ellard, S. L.
    Lee, U.
    Hirte, H.
    Sederias, J.
    Ivy, S. P.
    Eisenhauer, E. A.
    ANNALS OF ONCOLOGY, 2011, 22 (02) : 335 - 340
  • [48] ROSELLA - GOG-3073-ENGOT-OV72/MITO: A phase 3 study of relacorilant plus nab-paclitaxel vs. nab-paclitaxel in advanced, platinum-resistant ovarian cancer
    Olawaiye, Alexander
    Van Gorp, Toon
    Monk, Bradley
    Novak, Zoltan
    O'Malley, David
    Oaknin, Ana
    Herzog, Thomas
    Gladieff, Laurence
    Alvarez, Edwin
    Korach, Jacob
    Chan, John
    Nicum, Shibani
    Bishop, Erin
    Chudecka-Glaz, Anita
    Covens, Allan
    Muller, Carolyn
    Westhoff, Gina
    Fishman, David
    Dreiling, Lyndah
    Pashova, Hristina
    Tudor, Iulia Cristina
    Lorusso, Domenica
    GYNECOLOGIC ONCOLOGY, 2023, 176 : S153 - S154
  • [49] Combination therapy with Bevacizumab and GEMOX for patients with platinum-resistant recurrent ovarian cancers: A phase ll study
    Takano, M.
    Ikeda, Y.
    Oda, K.
    Kouta, H.
    Kudoh, K.
    Kita, T.
    Sasaki, N.
    Goto, T.
    Furuya, K.
    Kikuchi, Y.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S730 - S730
  • [50] Correction: Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer
    Dana M. Roque
    Eric R. Siegel
    Natalia Buza
    Stefania Bellone
    Dan-Arin Silasi
    Gloria S. Huang
    Vaagn Andikyan
    Mitchell Clark
    Masoud Azodi
    Peter E. Schwartz
    Gautam G. Rao
    Jocelyn C. Reader
    Pei Hui
    Joan R. Tymon-Rosario
    Justin Harold
    Dennis Mauricio
    Burak Zeybek
    Gulden Menderes
    Gary Altwerger
    Elena Ratner
    Alessandro D. Santin
    British Journal of Cancer, 2024, 130 : 1073 - 1073
12345